Veerhealth Care

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE882C01035
  • NSEID: NIYATILEAS
  • BSEID: 511523
INR
20.31
0.31 (1.55%)
BSENSE

Mar 19

BSE+NSE Vol: 55.1 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

55.1 k (-14.71%) Volume

Shareholding (Dec 2025)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

31.50%

how big is Veerhealth Care?

06-Jun-2025

As of Jun 06, Veerhealth Care Ltd has a market capitalization of 29.04 Cr, with net sales of 16.67 Cr and a net profit of 0.39 Cr for the latest four quarters. Shareholder's funds are 21.84 Cr, and total assets amount to 28.12 Cr as of Mar'24.

Market Cap: As of Jun 06, Veerhealth Care Ltd has a market capitalization of 29.04 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Veerhealth Care reported net sales of 16.67 Cr and a net profit of 0.39 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: The balance sheet data is also Standalone and pertains to the latest annual period ending in Mar'24. Shareholder's funds are reported at 21.84 Cr, while total assets amount to 28.12 Cr.

View full answer

When is the next results date for Veerhealth Care?

06-Jun-2025

No Upcoming Board Meetings

Who are in the management team of Veerhealth Care?

06-Jun-2025

As of March 2022, the management team of Veerhealth Care includes Shruti Y Shah (Executive Director), Bhavin S Shah (Managing Director), and several independent and non-executive directors, with varying remuneration levels. The team is responsible for the governance and management of the company.

As of March 2022, the management team of Veerhealth Care includes the following individuals:<BR><BR>1. Shruti Y Shah - Executive Director (Remuneration: Rs. 5.2 lacs)<BR>2. Arvind M Shah - Independent Director (Remuneration: Rs. 1.0 k)<BR>3. Yogesh M Shah - Chairman & Independent Director (Remuneration: Rs. 0)<BR>4. Bhavin S Shah - Managing Director (Remuneration: Rs. 9.6 lacs)<BR>5. Dharnendra B Shah - Independent Director (Remuneration: Rs. 1.0 k)<BR>6. Mitesh J Kuvadia - Independent Director (Remuneration: Rs. 2.0 k)<BR>7. Rony M Shah - Company Secretary & Compliance Officer (Remuneration: Rs. 5.72 lacs)<BR>8. Chetan H Mehta - Non-Executive Director (Remuneration: Rs. 0)<BR>9. Prakash C Shah - Non-Executive Director (Remuneration: Rs. 0)<BR>10. Nilesh Kantilal Shah - Non-Executive Director (Remuneration: Rs. 0)<BR><BR>This team comprises a mix of executive, independent, and non-executive directors, each contributing to the governance and management of the company.

View full answer

What does Veerhealth Care do?

06-Jun-2025

Veerhealth Care Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, originally incorporated in 1992 and renamed in 2013. As of March 2025, it reported net sales of 6 Cr and a market cap of Rs 30 Cr.

Overview:<BR>Veerhealth Care Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated on 10 July, 1992, as Niyati Leasing Limited. It underwent several name changes, first to Niyati Industries Limited in 1998 and then to Veerhealth Care Limited in May 2013. The latest quarterly results report net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 6 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2025)<BR>- Market-cap: Rs 30 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 30.00<BR>- Industry P/E: 30<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.17<BR>- Return on Equity: 1.76%<BR>- Price to Book: 1.35<BR><BR>Contact Details:<BR>Address: 629-A 1st Floor Gazdar House, JSS Marg Nr Kalbadevi Post Off Mumbai Maharashtra : 400002<BR>Tel: 91-22-22018582<BR>Email: info@veerhealthcare.net<BR>Website: http://www.veerhealthcare.net

View full answer

What is the bonus history of the Veerhealth Care?

06-Jun-2025

Veerhealth Care recently issued a 1:1 bonus share on September 22, 2023, meaning shareholders received an additional share for each share held. The record date for this bonus was also September 22, 2023.

Veerhealth Care has a recent bonus history that includes a 1:1 bonus issue announced with an ex-date of September 22, 2023. This means that for every share held, shareholders received an additional share. The record date for this bonus was also September 22, 2023. If you have any more questions about Veerhealth Care or need further details, feel free to ask!

View full answer

Has Veerhealth Care declared dividend?

06-Jun-2025

No Dividend History Available

Who are the peers of the Veerhealth Care?

03-Jun-2025

Veerhealth Care's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Colinz Labs, Vineet Laborator, Zenith Health, and Ishita Drugs. It has below-average management risk and growth compared to its peers, with a 1-year return of -23.83%.

Peers: The peers of Veerhealth Care are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Colinz Labs, Vineet Laborator, Zenith Health, and Ishita Drugs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Below Average management risk is seen at Veerhealth Care, Colinz Labs, Zenith Health, Ishita Drugs, and the rest. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted for Divi's Lab., Torrent Pharma, Veerhealth Care, Colinz Labs, Vineet Laborator, Zenith Health, Ishita Drugs, and the rest. Excellent capital structure is present at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good capital structure is found at Torrent Pharma, Veerhealth Care, Colinz Labs, Zenith Health, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while the peer with the lowest is Vineet Laborator at -46.35%. Veerhealth Care's 1-year return is -23.83%, which is higher than Vineet Laborator's but lower than all other peers. Additionally, the six-month return is negative for Veerhealth Care, Cipla, Torrent Pharma, Dr Reddy's Labs, Vineet Laborator, Zenith Health, and Ishita Drugs.

View full answer

Is Veerhealth Care overvalued or undervalued?

09-Jun-2025

As of February 13, 2025, Veerhealth Care is considered overvalued with a PE ratio of 30.00 and an EV to EBITDA of 33.75, despite recent strong stock performance, indicating a shift in sentiment from very expensive to risky compared to peers like Elitecon International and Lloyds Enterprises.

As of 13 February 2025, Veerhealth Care's valuation grade has moved from very expensive to risky, indicating a shift in investor sentiment. The company is currently assessed as overvalued. Key ratios include a PE ratio of 30.00, an EV to EBITDA of 33.75, and a ROE of 1.76%. <BR><BR>In comparison to its peers, Veerhealth Care's PE ratio is significantly lower than that of Elitecon International, which stands at 131.08, and also lower than Lloyds Enterprises at 156.59. However, it is on par with MMTC, which has a PE ratio of 119.39. Notably, the company's recent stock performance has outpaced the Sensex in the short term, with a 1-week return of 9.80% compared to the Sensex's 1.43%. This suggests some short-term investor interest, but the overall valuation still leans towards overvaluation given the broader financial metrics.

View full answer

What is the technical trend for Veerhealth Care?

09-Jun-2025

As of May 12, 2025, Veerhealth Care shows a mildly bearish trend overall, with mixed indicators suggesting short-term weakness despite a current price of 16.47, which is above the previous close of 15.00.

As of 12 May 2025, the technical trend for Veerhealth Care has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD indicates a mildly bearish stance. The moving averages on a daily basis are also mildly bearish, suggesting short-term weakness. Bollinger Bands show a bullish signal on the weekly timeframe but are mildly bearish monthly. The KST reflects a mildly bullish trend weekly while being mildly bearish monthly. Overall, the indicators present a mixed picture, with a slight bearish bias prevailing in the longer term. The current price of 16.47 is above the previous close of 15.00, but the stock has underperformed significantly over the past year. The overall stance is mildly bearish with moderate strength.

View full answer

Who are the top shareholders of the Veerhealth Care?

17-Jul-2025

The top shareholder of Veerhealth Care is Yogesh Mahasuklal Shah, with an 11.03% stake, followed by public shareholder Deval Nilay Shah at 2.68%. Individual investors collectively own 57.92% of the shares, with no mutual funds or foreign institutional investors involved.

The top shareholders of Veerhealth Care include Yogesh Mahasuklal Shah, who holds the highest stake at 11.03%. The highest public shareholder is Deval Nilay Shah, with a holding of 2.68%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 57.92% of the shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

View full answer

Are Veerhealth Care latest results good or bad?

13-Nov-2025

Veerhealth Care's latest results are concerning, showing a slight profit increase but significant revenue declines of 11.36% quarter-on-quarter and 22.72% year-on-year, alongside low profitability metrics. Overall, the financial outlook suggests ongoing challenges in achieving consistent growth.

Veerhealth Care's latest results present a mixed picture, leaning towards the negative side. In Q2 FY26, the company reported a net profit of ₹0.25 crores, which is a slight increase of 4.17% from the previous quarter. However, this figure represents a significant decline of 16.67% compared to the same quarter last year. <BR><BR>Revenue for the same period was ₹3.98 crores, reflecting a concerning drop of 11.36% quarter-on-quarter and a substantial decline of 22.72% year-on-year. This ongoing revenue contraction indicates serious challenges in maintaining market traction and suggests that the company is struggling to achieve consistent growth in a competitive pharmaceutical landscape.<BR><BR>While the operating margin improved to 13.32%, up from -0.67% in the previous quarter, this improvement is overshadowed by the revenue decline and raises questions about the sustainability of profitability. The company's overall performance is further complicated by its low return on equity of 2.72% and negative return on capital employed, indicating inefficiencies in generating returns from its investments.<BR><BR>Given these factors, the financial outlook for Veerhealth Care appears troubling, with persistent revenue challenges and weak profitability metrics suggesting that the latest results are more indicative of underlying issues rather than a positive turnaround.

View full answer

How has been the historical performance of Veerhealth Care?

26-Nov-2025

Veerhealth Care's historical performance shows net sales growth from 9.63 Cr in Mar'22 to 16.67 Cr in Mar'25, but profitability has fluctuated, with profit after tax declining from 1.58 Cr in Mar'23 to 0.39 Cr in Mar'25. Total assets increased significantly, while cash flow from operating activities dropped to 0.00 Cr in Mar'25.

Answer:<BR>The historical performance of Veerhealth Care shows a fluctuating trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Veerhealth Care's net sales have increased from 9.63 Cr in Mar'22 to 16.67 Cr in Mar'25, indicating a positive growth trajectory. Total operating income followed a similar pattern, rising from 9.63 Cr in Mar'22 to 16.67 Cr in Mar'25. The company's total expenditure also grew, reaching 16.21 Cr in Mar'25 from 10.45 Cr in Mar'22. Operating profit (PBDIT) fluctuated, peaking at 2.00 Cr in Mar'24 before dropping to 1.68 Cr in Mar'25. Profit before tax showed variability, with a notable increase to 1.28 Cr in Mar'24 but declining to 0.51 Cr in Mar'25. Profit after tax was 0.39 Cr in Mar'25, down from 1.58 Cr in Mar'23. The company's total assets increased significantly from 20.15 Cr in Mar'22 to 33.77 Cr in Mar'25, while total liabilities also rose from 20.15 Cr to 33.77 Cr in the same period. Cash flow from operating activities was 0.00 Cr in Mar'25, contrasting with 2.00 Cr in Mar'24, while cash flow from investing activities showed a negative trend at -8.00 Cr in Mar'25. Overall, Veerhealth Care's financial performance reflects both growth in sales and assets, alongside challenges in profitability and cash flow management.

View full answer

Should I buy, sell or hold Veerhealth Care Ltd?

26-Feb-2026

Why is Veerhealth Care Ltd falling/rising?

13-Mar-2026

As of 13-Mar, Veerhealth Care Ltd's stock price is at 19.93, down 0.45%, but has a year-to-date increase of 3.10% and a 55.22% rise over the past year. Despite today's decline, the stock shows strong long-term growth potential and increased investor interest.

As of 13-Mar, Veerhealth Care Ltd's stock price is currently at 19.93, reflecting a decrease of 0.09 or 0.45%. Despite this decline, the stock has shown a strong performance over the longer term, with a year-to-date increase of 3.10% and a remarkable 55.22% rise over the past year. <BR><BR>Today, the stock has outperformed its sector by 1.26%, indicating relative strength compared to peers. However, it is important to note that this decline follows three consecutive days of gains, suggesting a potential trend reversal. Additionally, the stock is trading above its moving averages across various time frames, which typically indicates a bullish trend.<BR><BR>Investor participation has also increased, with delivery volume rising by 109.25% compared to the 5-day average, indicating heightened interest in the stock. Despite the current price drop, the overall liquidity remains sufficient for trading, as it is based on 2% of the 5-day average traded value.<BR><BR>In summary, while Veerhealth Care Ltd is experiencing a slight decline in price today, the overall performance metrics and increased investor participation suggest a resilient stock with strong long-term growth potential.

View full answer

Why is Veerhealth Care Ltd falling/rising?

14-Mar-2026

As of 14-Mar, Veerhealth Care Ltd's stock price is at 19.93, down 0.45% after a trend reversal from three days of gains. Despite this short-term decline, the stock has a year-to-date increase of 3.10% and a 55.22% rise over the past year, indicating strong overall performance and positive market sentiment.

As of 14-Mar, Veerhealth Care Ltd's stock price is currently at 19.93, reflecting a decrease of 0.09 or 0.45%. This decline comes after a trend reversal, as the stock had experienced three consecutive days of gains prior to this drop. Despite this short-term decrease, the stock has shown strong performance over longer periods, with a year-to-date increase of 3.10% compared to a 12.50% decline in the Sensex, and a remarkable 55.22% rise over the past year.<BR><BR>Additionally, the stock is trading above its moving averages across various time frames, indicating a generally positive trend. Investor participation has also increased, with a significant rise in delivery volume, which was up by 109.25% against the five-day average. This suggests that while the stock is experiencing a slight decline today, the overall sentiment and performance indicators remain strong, contributing to its resilience in the market.

View full answer

Why is Veerhealth Care Ltd falling/rising?

15-Mar-2026

As of 15-Mar, Veerhealth Care Ltd's stock price is at 19.93, down 0.45%. Despite a recent decline, the stock has strong long-term performance, with a year-to-date increase of 3.10% and a 55.22% rise over the past year, indicating resilience in the market.

As of 15-Mar, Veerhealth Care Ltd's stock price is currently at 19.93, reflecting a decrease of 0.09 or 0.45%. The stock has experienced a trend reversal, having fallen after three consecutive days of gains. Despite this recent decline, the stock has shown strong performance over longer periods, with a year-to-date increase of 3.10% compared to a 12.50% decline in the benchmark Sensex. Over the past year, Veerhealth Care has risen by 55.22%, significantly outperforming the Sensex, which only increased by 1.00%.<BR><BR>Additionally, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a generally positive trend. Investor participation has also increased, with delivery volume rising by 109.25% against the 5-day average, suggesting heightened interest in the stock. However, the current drop in price may be attributed to a natural correction after the recent gains, rather than a fundamental weakness in the stock itself. Overall, while the stock is currently falling, its longer-term performance and increased investor activity indicate a resilient position in the market.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 2.72%

  • Poor long term growth as Net Sales has grown by an annual rate of 11.75% and Operating profit at 7.26% over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -0.28
2

With ROCE of -1.7, it has a Very Expensive valuation with a 1.7 Enterprise value to Capital Employed

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 41 Cr (Micro Cap)

stock-summary
P/E

51.00

stock-summary
Industry P/E

23

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.17

stock-summary
Return on Equity

3.56%

stock-summary
Price to Book

1.80

Revenue and Profits:
Net Sales:
7 Cr
(Quarterly Results - Dec 2025)
Net Profit:
0 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
13.78%
0%
13.78%
6 Months
11.78%
0%
11.78%
1 Year
53.17%
0%
53.17%
2 Years
-3.74%
0%
-3.74%
3 Years
126.17%
0%
126.17%
4 Years
261.71%
0%
261.71%
5 Years
438.73%
0%
438.73%

Veerhealth Care for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Veerhealth Care Ltd’s Mixed Week: -0.61% Price, Outperformance vs Sensex

Announcements stock-summary

Announcement under Regulation 30 (LODR)-Investor Presentation

25-Feb-2026 | Source : BSE

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith Investors Presentation of the Company. The presentation is also being made available on the Companys Website www.veerhealthcare.net.

Announcement under Regulation 30 (LODR)-Investor Presentation

25-Feb-2026 | Source : BSE

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith Investors Presentation of the Company. The presentation is also being made available on the Companys Website www.veerhealthcare.net.

Announcement under Regulation 30 (LODR)-Newspaper Publication

16-Feb-2026 | Source : BSE

Extract of financial result published in newspaper is attached.

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

Veerhealth Care Ltd has announced 10:1 stock split, ex-date: 29 Nov 16

stock-summary
BONUS

Veerhealth Care Ltd has announced 1:1 bonus issue, ex-date: 22 Sep 23

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
11.75%
EBIT Growth (5y)
7.26%
EBIT to Interest (avg)
-0.28
Debt to EBITDA (avg)
1.55
Net Debt to Equity (avg)
0.17
Sales to Capital Employed (avg)
0.62
Tax Ratio
15.96%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
-0.45%
ROE (avg)
2.72%

Valuation key factors

Factor
Value
P/E Ratio
51
Industry P/E
23
Price to Book Value
1.80
EV to EBIT
43.75
EV to EBITDA
27.86
EV to Capital Employed
1.68
EV to Sales
2.05
PEG Ratio
0.04
Dividend Yield
NA
ROCE (Latest)
-1.73%
ROE (Latest)
3.56%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Non Institution

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Yogesh Mahasuklal Shah (11.03%)

Highest Public shareholder

Rishabh Fintrade (2.72%)

Individual Investors Holdings

55.12%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 82.41% vs -11.36% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 60.00% vs 4.17% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.26",
          "val2": "3.98",
          "chgp": "82.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.24",
          "val2": "0.53",
          "chgp": "133.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.40",
          "val2": "0.25",
          "chgp": "60.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "17.08%",
          "val2": "13.32%",
          "chgp": "3.76%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 17.48% vs -2.70% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 16.67% vs -42.47% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8.47",
          "val2": "7.21",
          "chgp": "17.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.50",
          "val2": "0.47",
          "chgp": "6.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.11",
          "chgp": "81.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.49",
          "val2": "0.42",
          "chgp": "16.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "5.90%",
          "val2": "6.52%",
          "chgp": "-0.62%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 42.35% vs 7.49% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 81.63% vs -46.74% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15.73",
          "val2": "11.05",
          "chgp": "42.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.74",
          "val2": "0.63",
          "chgp": "176.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.12",
          "chgp": "150.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.89",
          "val2": "0.49",
          "chgp": "81.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "11.06%",
          "val2": "5.70%",
          "chgp": "5.36%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 26.10% vs -0.38% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -4.88% vs -74.05% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "16.67",
          "val2": "13.22",
          "chgp": "26.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.46",
          "val2": "0.61",
          "chgp": "-24.59%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.26",
          "val2": "0.01",
          "chgp": "2,500.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.39",
          "val2": "0.41",
          "chgp": "-4.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "2.76%",
          "val2": "4.61%",
          "chgp": "-1.85%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
7.26
3.98
82.41%
Operating Profit (PBDIT) excl Other Income
1.24
0.53
133.96%
Interest
0.10
0.10
Exceptional Items
0.00
0.00
Standalone Net Profit
0.40
0.25
60.00%
Operating Profit Margin (Excl OI)
17.08%
13.32%
3.76%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is 82.41% vs -11.36% in Sep 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Dec 2025 is 60.00% vs 4.17% in Sep 2025

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
8.47
7.21
17.48%
Operating Profit (PBDIT) excl Other Income
0.50
0.47
6.38%
Interest
0.20
0.11
81.82%
Exceptional Items
0.00
0.00
Standalone Net Profit
0.49
0.42
16.67%
Operating Profit Margin (Excl OI)
5.90%
6.52%
-0.62%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 17.48% vs -2.70% in Sep 2024

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2025 is 16.67% vs -42.47% in Sep 2024

Nine Monthly Results Snapshot (Standalone) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
15.73
11.05
42.35%
Operating Profit (PBDIT) excl Other Income
1.74
0.63
176.19%
Interest
0.30
0.12
150.00%
Exceptional Items
0.00
0.00
Standalone Net Profit
0.89
0.49
81.63%
Operating Profit Margin (Excl OI)
11.06%
5.70%
5.36%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is 42.35% vs 7.49% in Dec 2024

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2025 is 81.63% vs -46.74% in Dec 2024

Annual Results Snapshot (Standalone) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
16.67
13.22
26.10%
Operating Profit (PBDIT) excl Other Income
0.46
0.61
-24.59%
Interest
0.26
0.01
2,500.00%
Exceptional Items
0.00
0.00
Standalone Net Profit
0.39
0.41
-4.88%
Operating Profit Margin (Excl OI)
2.76%
4.61%
-1.85%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 26.10% vs -0.38% in Mar 2024

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2025 is -4.88% vs -74.05% in Mar 2024

stock-summaryCompany CV
About Veerhealth Care Ltd stock-summary
stock-summary
Veerhealth Care Ltd
Micro Cap
Pharmaceuticals & Biotechnology
Veerhealth Care Limited was originally incorporated on 10 July, 1992 as Niyati Leasing Limited to start business in Investment and Finance. The main objects of the Company in 1998 got changed and accordingly the name of the Company was changed from Niyati Leasing Limited to Niyati Industries Limited and again to Veerhealth Care Limited in May, 2013. Initially in 2010, the Company was engaged into dealing and trading of shares, securities, debentures, and other investments.
Company Coordinates stock-summary
Company Details
629-A 1st Floor Gazdar House, JSS Marg Nr Kalbadevi Post Off Mumbai Maharashtra : 400002
stock-summary
Tel: 91-22-22018582
stock-summary
info@veerhealthcare.net
Registrar Details
Purva Shareregistry (India) Pvt Ltd , Gala No 9, Shiv Shakti, Industrial Estate,Sitaram Mill Comp., J R Boricha Marg, Lower Parel [E], Mumbai